The International Vaccines and Virology Conference welcomes you to London during June 10-11, 2021 to share your research findings, promote knowledge exchange and network with a broad audience in the field of microbiology and immunology.

i-Vaccines 2021 is an annual gathering for researchers, practitioners and educators to share the insights and discuss the recent innovations, research, concerns as well as practical challenges encountered, and development to improve the healthcare sector's preventive and cure needs. The conference’s global goal is to deliberate and disseminate innovative ideas among academics, research and development executives, scientists, industrialists, and policymakers to deepen the comprehension and transform the knowledge into innovative solutions for patient care. 

The i-Vaccines Operating Committee invites the submission of abstracts covering a broad range of cross-cutting topics, including Adaptive Immunity, Vaccines, and Gene Therapy, Viral Oncogenesis, Advances in viral diagnostics, Antiviral therapy, Cancer Vaccines and Immunotherapy, Hepatitis viruses, HIV, etc for information exchange and a fertile ground for the establishment and encouraging multidisciplinary collaborative studies.

Join us and witness the booming industry by taking part in i-Vaccines 2021 and giving new opportunities from around the world to your career and business. We'll be pleased to host you in London city.

The global market for vaccines is steered by the growth in infectious disease prevalence, as it is considered as one of the best ways to prevent these diseases. Immunization helps prevent almost 2 to 3 million deaths from influenza, tetanus, diphtheria, measles, pertussis and other diseases. According to the WHO, more than 1.5 million deaths can be avoided as a result of improved global coverage of vaccination.

In order to curb the rising healthcare costs, recognition of preventive care has triggered the interests of different governments, leading to increased funding from both national and international organizations for the development of advanced vaccine technologies, thus contributing to the growth of the preventive vaccine market over the forecast period. High per capita healthcare spending, high patient awareness and the high prevalence of target diseases are some of the factors that contribute to the growth of the region's industry. The global market for preventive vaccines is anticipated to reach USD 38,946.41 million by 2024. Recombinant vaccines were expected to see significant growth during the time of study due to fewer side effects of these vaccines compared to conventional ones resulting in high adoption and demand for recombinant vaccines. Molecular biology and genetic engineering developments will have a positive impact on recombinant vaccine market growth. Europe is anticipated to record the highest CAGR, which is attributed to enhanced healthcare infrastructure, facilitated diagnostics, and the growing affordability of diagnostic tests for viral diseases. On the basis of diagnosis tests, hepatitis B, Hepatitis C, HIV, Human papillomavirus (HPV), and other tests (like influenza, Ebola, and dengue) are estimated to hold the largest market share globally during the forecast period.